2型糖尿病合并慢性肾脏病联合治疗的比较有效性:真实世界数据
基于美国TriNetX协作网络的真实世界数据,采用目标试验模拟和倾向性评分匹配,分析2型糖尿病合并慢性肾脏病且eGFR 20-60 mL/min、已接受RAASi治疗的患者。与RAASi单药治疗相比,RAASi联合SGLT-2i或GLP1-RA均降低全因死亡风险,三联治疗降低幅度最大,且次要终点(复合终点和MAKE)也显示联合治疗更优。
要点
- 在已用RAASi的T2DM合并CKD患者中,加用SGLT-2i或GLP1-RA均降低死亡风险。
- 三联治疗(RAASi+SGLT-2i+GLP1-RA)死亡风险降低幅度最大。
- 联合治疗对复合终点和MAKE的风险降低优于RAASi单药,三联治疗最强。
核心结论
- 在已接受RAASi治疗的T2DM合并CKD患者中,SGLT-2i和GLP1-RA各自独立改善结局,三联治疗与更低的死亡和肾脏结局风险相关。
研究设计与样本
- 使用美国TriNetX协作网络数据的真实世界研究,采用目标试验模拟和倾向性评分匹配,首次用药者设计,对照为RAASi单药治疗。
- 纳入n=19,139例2型糖尿病合并慢性肾脏病且eGFR 20-60 mL/min、已接受RAASi治疗的患者。
主要发现
- 与RAASi单药相比,RAASi联合SGLT-2i的全因死亡aHR为0.602(95% CI 0.528-0.686)。
- 与RAASi单药相比,RAASi联合GLP1-RA的全因死亡aHR为0.597(95% CI 0.507-0.702)。
- 三联治疗的全因死亡aHR为0.317(95% CI 0.234-0.429)。
- 三联治疗对复合终点的aHR为0.414(95% CI 0.328-0.524),对MAKE的aHR为0.509(95% CI 0.374-0.693)。
临床怎么用
- 对于已使用RAASi的T2DM合并CKD患者,可考虑联合SGLT-2i或GLP1-RA以改善生存和肾脏结局。
- 三联治疗可能带来额外获益,但需结合患者具体情况评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Diabetes mellitus type 2 (T2DM) is the primary driver of chronic kidney disease (CKD). Renin-angiotensin-aldosterone system inhibitors (RAASi) represent basic therapy for CKD in T2DM. Recent studies demonstrated renal benefits of sodium glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA), but data on direct comparisons and potential additive effects of their combination remain unclear. METHODS: Using data from the US Collaborative Network in TriNetX, we analyzed patients with T2DM, CKD, and eGFR between 20-60 mL/min. A target-trial emulation with propensity score matching evaluated different drug combinations in first-user design versus RAASi monotherapy. Primary endpoint was all-cause mortality. Secondary outcomes included a composite endpoint of all-cause mortality and major adverse kidney events (MAKE), and MAKE as a distinct endpoint. MAKE was defined as CKD stage 5, end-stage renal disease, eGFR <15 mL/min, or need for renal replacement therapy. Kaplan-Meier analysis was used for survival analysis. RESULTS: We identified n= 19,139 patients with T2DM, an eGFR between 20-60mL/min and already established RAASi treatment. RAASi combined with SGLT-2i (aHR 0.602, 95% CI 0.528-0.686) or GLP1-RA (aHR 0.597, 95% CI 0.507-0.702) reduced mortality compared to RAASi monotherapy. Triple therapy showed the greatest mortality reduction (aHR 0.317, 95% CI 0.234-0.429). Secondary endpoints favored dual therapy over RAASi monotherapy, with triple therapy providing the strongest risk reduction for both composite endpoint (aHR 0.414, 95% CI 0.328-0.524) and MAKE (aHR 0.509, 95% CI 0.374-0.693). CONCLUSION: SGLT-2i and GLP1-RA independently improve outcomes in T2DM patients on RAASi treatment. Triple therapy was associated with lower risk for mortality and renal outcomes.
引用
- Casper J, Doricic J, Tian Z, et al. Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data. Nephrol Dial Transplant. 2026. PMID: 42658186. doi:10.1093/ndt/gfag198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。